RecruitingPhase 2NCT07502508

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants With Type 2 Diabetes Not Achieving Glycemic Targets Despite GLP-1-Based Therapy

Sponsor

Biomea Fusion Inc.

Enrollment

60 participants

Start Date

Apr 30, 2026

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes

Summary

This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called icovamenib 100 mg for people with type 2 diabetes. The study is currently recruiting participants at 16 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGicovamenib 100 mg

icovamenib 100 mg

DRUGPlacebo

Matching placebo

Locations(17)

Central Research Associates, LLC dba Flourish Research

Birmingham, Alabama, United States

Hope Clinical Research

Canoga Park, California, United States

Ark Clinical Research

Long Beach, California, United States

Catalina Research Institute, LLC

Montclair, California, United States

Paradigm Clinical Research Centers, LLC

San Diego, California, United States

Southwest General Healthcare Center

Fort Myers, Florida, United States

Panax Clinical Research

Miami Lakes, Florida, United States

Flourish Research Orlando

Winter Park, Florida, United States

David Kavtaradze MD, Inc

Cordele, Georgia, United States

Excel Clinical Research

Las Vegas, Nevada, United States

Diabetes and Endocrinology Associates of Stark County

Canton, Ohio, United States

Elligo Health Research, Inc.

Austin, Texas, United States

Zenos Clinical Research

Dallas, Texas, United States

Synergy Group Medical

Houston, Texas, United States

Epic Clinical Research

Lewisville, Texas, United States

Diabetes & Glandular Disease Clinic, P.A.

San Antonio, Texas, United States

Burke Internal Medicine and Research

Burke, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07502508

Related Trials

Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes

NCT076506821 location

THC Effects on Glucose in Type 2 Diabetes

NCT053222131 location

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT070111472 locations

Measurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality

NCT076413091 location

Mechanism of SGLT2 Inhibition in the Kidney

NCT062911551 location